Innate Pharma (IPHA) Total Non-Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has reported Total Non-Current Liabilities for 9 consecutive years, with $54.4 million the latest figure, recorded in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 31.01% year-over-year to $54.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $54.4 million (down 31.01% YoY) and the FY2025 annual result came in at $54.4 million, down 31.01% from the prior year.
• Total Non-Current Liabilities fell to $54.4 million in Q4 2025 per IPHA's latest filing, from $66.4 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for IPHA reached as high as $118.1 million in Q4 2022 and fell as low as $54.4 million in Q4 2025.
• A 5-year average of $92.4 million and a median of $95.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities slumped 99.76% — and 2022, when it gained 29.48%.
• Year by year, Total Non-Current Liabilities stood at $91.2 million in 2021, then advanced by 29.48% to $118.1 million in 2022, then decreased by 19.42% to $95.2 million in 2023, then fell by 17.22% to $78.8 million in 2024, then slumped by 31.01% to $54.4 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $54.4 million, $66.4 million, and $78.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.